Zupi G, Cavallari A, Greco C, Sacchi A
Anticancer Res. 1984 Jan-Apr;4(1-2):91-5.
Three Lewis lung carcinoma lines (3LL) with different metastatic behavior have been investigated with regard to their response to Razoxane (ICRF-159). The effects of different schedules were tested both on primary and secondary tumors. Results show that the lines are heterogeneous in their response to this antimetastatic agent and that, in particular, BM21548 the least metastatic line is also less sensitive to ICRF-159. A better response can be achieved with this line by a proper fractionation regimen which takes into account the delayed metastasis release from primary tumor. As far as M1087, the most metastatic line is concerned, secondaries are greatly affected by ICRF-159 treatment if performed at a moderately advanced stage of growth. On the contrary, metastases from early tumor stages can be better controlled by radical surgery of the primary implant than by treatment with ICRF-159.
对三种具有不同转移行为的Lewis肺癌细胞系（3LL）针对它们对丙亚胺（ICRF - 159）的反应进行了研究。测试了不同给药方案对原发性肿瘤和继发性肿瘤的影响。结果表明，这些细胞系对这种抗转移药物的反应具有异质性，特别是转移能力最弱的BM21548细胞系对ICRF - 159也不太敏感。通过适当的分次给药方案可以使该细胞系获得更好的反应，该方案考虑到了原发性肿瘤延迟释放转移灶的情况。就转移能力最强的M1087细胞系而言，如果在生长的中度晚期进行ICRF - 159治疗，继发性肿瘤会受到很大影响。相反，与ICRF - 159治疗相比，对早期肿瘤阶段的原发性植入物进行根治性手术可以更好地控制转移灶。
